Aminoglycoside-induced nephrotoxicity - A focus on monitoring: A review of literature

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The use of aminoglycoside (AG) antibiotics has declined over the past 15 years primarily due to comparable potency of other antimicrobials and the nephrotoxicity potential of AG drugs. However, resurgence in the use of AG antimicrobials is occurring due to multidrug-resistant gram-negative nosocomial infections. Multidrug-resistant Pseudomonas and Acinetobacter isolates as well as extended-spectrum beta-lactamase-producing Enterobacteriaceae continue to force clinicians to consider AG therapy for nosocomial infections in hospitalized patients and enterococcal endocarditis. Additionally, AGs are still indicated in the treatment of pulmonary exacerbations of cystic fibrosis. Along with the use of AG antibiotics is the associated renal insufficiency complication. This review discusses the mechanism for AG-induced nephrotoxicity. Patient- and drug-related risk factors are discussed to help identify patients at increased risk. The issue of serum-level monitoring is discussed relative to the development of nephrotoxicity.

Original languageEnglish
Pages (from-to)562-566
Number of pages5
JournalJournal of Pharmacy Practice
Volume27
Issue number6
DOIs
StatePublished - Dec 11 2014

Fingerprint

Aminoglycosides
Cross Infection
Anti-Bacterial Agents
Acinetobacter
Enterobacteriaceae
beta-Lactamases
Pseudomonas
Endocarditis
Cystic Fibrosis
Pharmaceutical Preparations
Renal Insufficiency
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Aminoglycoside-induced nephrotoxicity - A focus on monitoring : A review of literature. / Destache, Christopher J.

In: Journal of Pharmacy Practice, Vol. 27, No. 6, 11.12.2014, p. 562-566.

Research output: Contribution to journalArticle

@article{6d7616d8ae9f4b93b985fe852528fc0d,
title = "Aminoglycoside-induced nephrotoxicity - A focus on monitoring: A review of literature",
abstract = "The use of aminoglycoside (AG) antibiotics has declined over the past 15 years primarily due to comparable potency of other antimicrobials and the nephrotoxicity potential of AG drugs. However, resurgence in the use of AG antimicrobials is occurring due to multidrug-resistant gram-negative nosocomial infections. Multidrug-resistant Pseudomonas and Acinetobacter isolates as well as extended-spectrum beta-lactamase-producing Enterobacteriaceae continue to force clinicians to consider AG therapy for nosocomial infections in hospitalized patients and enterococcal endocarditis. Additionally, AGs are still indicated in the treatment of pulmonary exacerbations of cystic fibrosis. Along with the use of AG antibiotics is the associated renal insufficiency complication. This review discusses the mechanism for AG-induced nephrotoxicity. Patient- and drug-related risk factors are discussed to help identify patients at increased risk. The issue of serum-level monitoring is discussed relative to the development of nephrotoxicity.",
author = "Destache, {Christopher J.}",
year = "2014",
month = "12",
day = "11",
doi = "10.1177/0897190014546102",
language = "English",
volume = "27",
pages = "562--566",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Aminoglycoside-induced nephrotoxicity - A focus on monitoring

T2 - A review of literature

AU - Destache, Christopher J.

PY - 2014/12/11

Y1 - 2014/12/11

N2 - The use of aminoglycoside (AG) antibiotics has declined over the past 15 years primarily due to comparable potency of other antimicrobials and the nephrotoxicity potential of AG drugs. However, resurgence in the use of AG antimicrobials is occurring due to multidrug-resistant gram-negative nosocomial infections. Multidrug-resistant Pseudomonas and Acinetobacter isolates as well as extended-spectrum beta-lactamase-producing Enterobacteriaceae continue to force clinicians to consider AG therapy for nosocomial infections in hospitalized patients and enterococcal endocarditis. Additionally, AGs are still indicated in the treatment of pulmonary exacerbations of cystic fibrosis. Along with the use of AG antibiotics is the associated renal insufficiency complication. This review discusses the mechanism for AG-induced nephrotoxicity. Patient- and drug-related risk factors are discussed to help identify patients at increased risk. The issue of serum-level monitoring is discussed relative to the development of nephrotoxicity.

AB - The use of aminoglycoside (AG) antibiotics has declined over the past 15 years primarily due to comparable potency of other antimicrobials and the nephrotoxicity potential of AG drugs. However, resurgence in the use of AG antimicrobials is occurring due to multidrug-resistant gram-negative nosocomial infections. Multidrug-resistant Pseudomonas and Acinetobacter isolates as well as extended-spectrum beta-lactamase-producing Enterobacteriaceae continue to force clinicians to consider AG therapy for nosocomial infections in hospitalized patients and enterococcal endocarditis. Additionally, AGs are still indicated in the treatment of pulmonary exacerbations of cystic fibrosis. Along with the use of AG antibiotics is the associated renal insufficiency complication. This review discusses the mechanism for AG-induced nephrotoxicity. Patient- and drug-related risk factors are discussed to help identify patients at increased risk. The issue of serum-level monitoring is discussed relative to the development of nephrotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=84910054239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910054239&partnerID=8YFLogxK

U2 - 10.1177/0897190014546102

DO - 10.1177/0897190014546102

M3 - Article

C2 - 25124375

AN - SCOPUS:84910054239

VL - 27

SP - 562

EP - 566

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 6

ER -